Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Income from Continuing Operations (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Income from Continuing Operations data on record, last reported at 319240000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 115.91% to 319240000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 975339000.0, a 89.53% decrease, with the full-year FY2025 number at 803957000.0, down 74.94% from a year prior.
  • Income from Continuing Operations reached 319240000.0 in Q1 2026 per PCVX's latest filing, down from 247832000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for PCVX hit a ceiling of 39087000.0 in Q1 2022 and a floor of 319240000.0 in Q1 2026.
  • A 5-year average of 130105058.82 and a median of 111867000.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 168.73% in 2022, then grew 29.81% in 2024.
  • Tracing PCVX's Income from Continuing Operations over 5 years: stood at 79940000.0 in 2022, then crashed by 124.05% to 179108000.0 in 2023, then increased by 29.81% to 125711000.0 in 2024, then tumbled by 97.14% to 247832000.0 in 2025, then decreased by 28.81% to 319240000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for PCVX at 319240000.0 in Q1 2026, 247832000.0 in Q4 2025, and 213121000.0 in Q3 2025.